Nosocomial Pneumonia Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

(Albany, USA) DelveInsight's, "Nosocomial Pneumonia Pipeline Insight, 2024" report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in the Nosocomial Pneumonia pipeline landscape. It covers the Nosocomial Pneumonia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Nosocomial Pneumonia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Nosocomial Pneumonia Pipeline Report
• DelveInsight's Nosocomial Pneumonia pipeline report depicts a robust space with 13+ active players working to develop 13+ pipeline therapies for Nosocomial Pneumonia treatment.
• The leading companies working in the Nosocomial Pneumonia Market include Aridis Pharmaceuticals, AstraZeneca, BioVersys, Clarametyx Biosciences, Johnsons & Johnsons Pharmaceutical LLC, PriCara Inc., Merck Sharp & Dohme LLC, Pfizer, Bayer, Nektar Therapeutics, Orlando Health Inc., Medline Industries, Cubist Pharmaceuticals LLC, Peninsula Pharmaceuticals Inc., and others.
• Promising Nosocomial Pneumonia Pipeline Therapies in the various stages of development include Ceftolozane/Tazobactam, meropenem (active comparator), Amikacin inhalation solution (BAY41-6551), and others.
• October 2023: Merck Sharp & Dohme LLC announced a study of Phase 1 clinical trials for Ceftolozane/Tazobactam. This is a phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosocomial pneumonia (NP). A Phase 1, Open-label, Non-comparative, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ceftolozane/Tazobactam (MK-7625A) in Pediatric Participants With Nosocomial Pneumonia.
• August 2023: Pfizer announced a study of Phase 4 clinical trials for Zavicefta, Ceftazidime-Avibactam. This is a prospective, single arm, open-label, multi-center clinical study evaluating the effectiveness and safety of CAZ-AVI in participants with HAP (including VAP), who have initiated treatment with CAZ-AVI in an inpatient hospital setting. The duration of antibiotic treatment with the CAZ-AVI is 7-14 days. Participants must receive intravenously (IV) CAZ-AVI in the hospital for at least 7 full days. There are no formal hypothesis tests planned for this study. The number and percent of participants having clinical cure, failure, and indeterminate at TOC visit in the cMITT analysis population will be summarized.
• May 2023: Basilea Pharmaceutical announced a study of Phase 3 clinical trials for Ceftobiprole medocaril. This was a study of the safety and efficacy of ceftobiprole medocaril compared with intravenous (IV) standard-of-care cephalosporin treatment with or without vancomycin in pediatric patients with either hospital-acquired bacterial pneumonia (HAP) or community-acquired bacterial pneumonia (CAP) requiring hospitalization, and requiring intravenous (IV) antibiotic therapy. A Multicentre, Randomized, Investigator-blind, Active-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Ceftobiprole Versus Intravenous Standard-of-care Cephalosporin Treatment With or Without Vancomycin in Pediatric Patients Aged From 3 Months to Less Than 18 Years With Hospital-acquired Pneumonia or Community-acquired Pneumonia Requiring Hospitalisation.

Request a sample and discover the recent advances in Nosocomial Pneumonia Treatment Drugs @ Nosocomial Pneumonia Pipeline Report- https://www.delveinsight.com/report-store/nosocomial-pneumonia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

In the Nosocomial Pneumonia pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nosocomial pneumonia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Nosocomial Pneumonia Overview
Nosocomial pneumonia, also known as hospital-acquired pneumonia (HAP), is a type of lung infection that occurs 48 hours or more after a patient is admitted to the hospital and was not incubating at the time of admission. It is a significant cause of morbidity and mortality in hospitalized patients. The most common pathogens involved include Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and other Gram-negative bacilli.
Risk factors for nosocomial pneumonia include mechanical ventilation, prolonged hospital stays, underlying chronic illnesses, immune suppression, and invasive procedures. Symptoms of HAP can include cough, fever, chills, shortness of breath, chest pain, and increased production of purulent sputum.
Diagnosis is based on clinical presentation, chest imaging (such as X-ray or CT scan), and microbiological analysis of respiratory secretions. Blood tests and cultures may also be used to identify the causative organism.
Treatment involves prompt initiation of broad-spectrum antibiotics, which are later tailored based on specific pathogen identification and antibiotic susceptibility results. Preventative measures include hand hygiene, infection control protocols, proper sterilization of medical equipment, and measures to prevent ventilator-associated pneumonia, such as elevating the head of the bed and ensuring adequate oral care.
Effective management of nosocomial pneumonia requires a multidisciplinary approach to minimize the risk of complications and improve patient outcomes.

Find out more about Nosocomial Pneumonia Therapeutics Assessment @ Nosocomial Pneumonia Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/nosocomial-pneumonia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Nosocomial Pneumonia Emerging Drugs Profile
• Tosatoxumab: Aridis Pharmaceuticals
• Suvratoxumab: AstraZeneca
• Rifabutin: BioVersys
• CMTX 101 : Clarametyx Biosciences

Nosocomial Pneumonia Pipeline Therapeutics Assessment
There are approx. 13+ key companies which are developing the Nosocomial Pneumonia therapies. The Nosocomial Pneumonia companies which have their Nosocomial Pneumonia drug candidates in the most advanced stage, i.e. phase III include, Aridis Pharmaceuticals.

DelveInsight's Nosocomial Pneumonia Pipeline Report covers around 13+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Nosocomial Pneumonia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Nosocomial Pneumonia Pipeline Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Learn more about the emerging Nosocomial Pneumonia Pipeline Therapies @ Nosocomial Pneumonia Clinical Trials Assessment- https://www.delveinsight.com/sample-request/nosocomial-pneumonia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Nosocomial Pneumonia Pipeline Report
• Coverage- Global
• Nosocomial Pneumonia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Nosocomial Pneumonia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Nosocomial Pneumonia Companies- Aridis Pharmaceuticals, AstraZeneca, BioVersys, Clarametyx Biosciences, Johnsons & Johnsons Pharmaceutical LLC, PriCara Inc., Merck Sharp & Dohme LLC, Pfizer, Bayer, Nektar Therapeutics, Orlando Health Inc., Medline Industries, Cubist Pharmaceuticals LLC, Peninsula Pharmaceuticals Inc., and others.
• Nosocomial Pneumonia Pipeline Therapies- Ceftolozane/Tazobactam, meropenem (active comparator), Amikacin inhalation solution (BAY41-6551), and others.

Dive deep into rich insights for new drugs for Nosocomial Pneumonia Treatment, Visit @ Nosocomial Pneumonia Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/nosocomial-pneumonia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Nosocomial Pneumonia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Nosocomial Pneumonia- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Tosatoxumab: Aridis Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Suvratoxumab: AstraZeneca
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Rifabutin : BioVersys
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. CMTX 101 : Clarametyx Biosciences
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Nosocomial Pneumonia Key Companies
21. Nosocomial Pneumonia Key Products
22. Nosocomial Pneumonia- Unmet Needs
23. Nosocomial Pneumonia- Market Drivers and Barriers
24. Nosocomial Pneumonia- Future Perspectives and Conclusion
25. Nosocomial Pneumonia Analyst Views
26. Nosocomial Pneumonia Key Companies
27. Appendix

For further information on the Nosocomial Pneumonia Pipeline therapeutics, reach out to Nosocomial Pneumonia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/nosocomial-pneumonia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Biochips Market: https://www.delveinsight.com/report-store/biochips-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Pain Management Devices Market: https://www.delveinsight.com/report-store/pain-management-devices-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-epidemiology-forecast
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Bartonellosis Market: https://www.delveinsight.com/report-store/bartonellosis-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Ocular Motility Disturbance Market: https://www.delveinsight.com/report-store/ocular-motility-disturbance-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.